Business Health Science

Gastro-Esophageal Junction Neuroendocrine Tumor Market Insight, Epidemiology and Market Forecast – 2028

Gastro-Esophageal Junction Neuroendocrine Tumor market
Gorlin Syndrome market
Press Release

DelveInsight’s Gastro-Esophageal Junction Neuroendocrine Tumor Market Insights, Epidemiology, and Market Forecast-2028-United States

The report provides an in-depth understanding of the disease historical and forecasted epidemiology as well as the market trends of Gastro-Esophageal Junction Neuroendocrine Tumor in the United States.

The Gastro-Esophageal Junction Neuroendocrine Tumor Market report provides current treatment practices, emerging drugs, Gastro-Esophageal Junction Neuroendocrine Tumor Market share of the individual therapies, current & forecasted Gastro-Esophageal Junction Neuroendocrine Tumor Market Size from 2017 to 2030 in the United States market. The Report also covers current Gastro-Esophageal Junction Neuroendocrine Tumor treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States

Study Period: 2017-2028

Gastro-Esophageal Junction Neuroendocrine Tumor Indication

Neuroendocrine carcinoma (NEC) of the esophagus and gastric cardia is a rare tumor, and the Chaoshan region has one of the biggest incidences of esophageal and gastric cardia cancer (GCC) worldwide. The majority of esophageal and gastric cardia NECs was of the small cell type, and 24/67 esophageal and 5/13 gastric cardia patients were found with lymph node metastasis. Immunohistochemistry was performed in all cases, and positive staining for synaptophysin (Syn) was found for all cases, with half the esophageal NEC cases being also chromogranin A (CgA)-positive.

Get a free sample page:- Gastro-Esophageal Junction Neuroendocrine Tumor Market Insight 2028

Gastro-Esophageal Junction Neuroendocrine Tumor Disease Understanding and Treatment Algorithm

The Gastro-Esophageal Junction Neuroendocrine Tumor is defined as the poorly differentiated area where the distal (lower) esophagus joins the proximal stomach (cardia). The Gastro-Esophageal Junction Neuroendocrine Tumor is remarkable because of the epithelial progress that happens there. Now, there is a move from the stratified squamous epithelium of the esophagus to the basic columnar epithelium of the stomach.

DelveInsight’s Gastro-Esophageal Junction Neuroendocrine Tumor market report gives a thorough understanding of the GEJ-NET by including details such as disease definition, classification, symptoms, etiology, Gastro-Esophageal Junction Neuroendocrine Tumor pathophysiology, Gastro-Esophageal Junction Neuroendocrine Tumor diagnostic trends. It also gives treatment algorithms and treatment guidelines for Gastro-Esophageal Junction Neuroendocrine Tumor in the US.

Gastro-Esophageal Junction Neuroendocrine Tumor Epidemiology

The Gastro-Esophageal Junction Neuroendocrine Tumor epidemiology division provide insights about historical and current patient pool and forecasted trend for the United States. It assists with perceiving the reasons for current and estimated trends by exploring various numerous studies and perspectives on key opinion pioneers(leaders). This piece of the DelveInsight’s report additionally gives the analyzed patient pool and their patterns alongside suppositions embraced.

The Gastro-Esophageal Junction Neuroendocrine Tumor disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Diagnosed Prevalent Population, and Grade -Specific Diagnosed Prevalent Population] scenario of Gastro-Esophageal Junction Neuroendocrine Tumor (GEJ-NET) in the United States from 2017-2028.

As per DelveInsight’s estimates, the Gastro-Esophageal Junction Neuroendocrine Tumor accounts for ~61% of all NET cases. We have also observed that the frequency of esophagus and stomach was accounted 0.24% (0.39% of GEP-NETs) and 6.02% (9.79% of GEP-NETs), respectively of all NET cases. Of all Esophagus NET, upper-middle esophagus NET comprised of a significantly lesser proportion of the patients, as compared to lower esophagus NET, whereas of all Gastric NET cases, gastric cardia NETs account for approximately 11% and gastric non cardia NET accounts for ~89% cases.

DelveInsight’s estimations suggest that the total diagnosed prevalent population of Gastro-Esophageal Junction Neuroendocrine Tumor in the United States was assessed to be 588 in 2017. The diagnosed prevalent cases in the United States is expected to increase with the CAGR of XX% for the study period of 2017-2028.

Furthermore, our estimations suggests that in the Grade-Specific segmentation of Gastro-Esophageal Junction Neuroendocrine Tumor, majority of the cases were observed for Grade 3 (poorly differentiated and undifferentiated or anaplastic), followed by the number of cases for Grade 1 (well differentiated), while Grade 2 (moderately differentiated) accounted for least percentage of patient pool.

Gastro-Esophageal Junction Neuroendocrine Tumor Drug Chapters

This segment of the Gastro-Esophageal Junction Neuroendocrine Tumor report encases the deep analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also assists to know the clinical trial details, expressive pharmacological activity, understandings and joint efforts, endorsement and patent subtleties, advantages and drawbacks of each included medication or drugs and the most recent news & press releases.

Lutathera is a radio-labeled somatostatin analog indicated for the treatment of somatostatin receptor-positive Gastroenteropancreatic Neuroendocrine Tumors including foregut, midgut, and hindgut neuroendocrine tumors in adults. The drug is administered intravenously. Lutetium Lu 177 dotatate binds to somatostatin receptors with the highest affinity for subtype 2 receptors (SSRT2). Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized. The beta emission from Lu 177 induces cellular damage by the formation of free radicals in somatostatin receptor-positive cells and in neighboring cells. The drug or medication belongs to the peptide receptor radionuclide therapy (PRRT) class, which carries a radioactive component for treatment.

Gastro-Esophageal Junction Neuroendocrine Tumor Market Outlook

The Gastro-Esophageal Junction Neuroendocrine Tumor market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Gastro-Esophageal Junction Neuroendocrine Tumor market trends by investigating the effect of extant therapies or treatments on the market available, neglected needs, drivers and boundaries and request of better technology.

This segment gives a thorough detail of Gastro-Esophageal Junction Neuroendocrine Tumor market trend of each promoted medication or drug and late-arrange pipeline treatment by assessing their effect dependent on annual cost of treatment or therapy, inclusion and exclusion criteria’s, and mechanism of action, compliance rate, developing need of the market, expanding patient pool, secured patient segment, expected launch year, rivalry with different treatments, brand esteem, their effect available and perspective on the key opinion leaders. The determined market information are given significant tables and charts to give a clear picture of the market from at first sight.

Gastro-Esophageal Junction Neuroendocrine Tumor involves cases of lower esophageal andGastro-Esophageal Junction Neuroendocrine Tumor. The treatment options include surgery (esophagectomy), chemotherapy, radiotherapy, and endoscopic treatment.

In addition, the current treatment options for Gastro-Esophageal Junction Neuroendocrine Tumor includes off-label products (chemotherapy and cytotoxic agents) and targeted therapies that are being used for the treatment of GEJ-NETs are contributing towards the market revenue of Gastro-Esophageal Junction Neuroendocrine Tumor. Cytotoxic therapies such as 5-FU, or temozolomide are considered in the palliation of patients with advanced Gastro-Esophageal Junction Neuroendocrine Tumor and symptoms related to tumor bulk. Furthermore, surgical treatment is the main method used to cure the disease.

The Gastro-Esophageal Junction Neuroendocrine Tumor market size in the United States is USD 24.98 Million in 2017, which is expected to increase at a CAGR of XX % for the study period (2017-2028). The therapeutic market of Gastro-Esophageal Junction Neuroendocrine Tumor is dominated by Somatostain Analogues (Lanreotide Depot/ Octreotide LAR), Neo-Adjuvant Chemotherapies (cisplatin/etoposide) and Chemo combination regimen (capecitabine and temozolomide). The market size of Gastro-Esophageal Junction Neuroendocrine Tumor first line treatment (which includes Neo-Adjuvant Chemotherapies (cisplatin/etoposide) and Somatostain Analogues (Lanreotide Depot/ Octreotide LAR)) was found to be USD XXX Million in 2017. Moreover, the expected launch of two potential therapies by 2028 may provide better treatment options for Gastro-Esophageal Junction Neuroendocrine Tumor patients.

Gastro-Esophageal Junction Neuroendocrine Tumor Drugs Uptake

This segment focuses on the pace of take-up of the potential medications or drugs as of late propelled in the Gastro-Esophageal Junction Neuroendocrine Tumor market or expected to get launched in the market during the study period 2017-2030. The analysis covers Gastro-Esophageal Junction Neuroendocrine Tumor market uptake by drugs; patient uptake by therapies; and sales of each drug.

This assists in understanding the medications or drugs with the quickest take-up, reasons behind the maximal use of new drugs and permit the examination of the drugs on the basis of market share and size which again will be helpful in researching factors significant in showcase take-up and in making financial and administrative decisions.

Due to the complexity of the disease, not many companies are targeting this disease. However, a few pharmaceutical giants are developing their therapies for the treatment of Gastroenteropancreatic Neuroendocrine tumor which includes foregut (esophagus, stomach, proximal duodenum, liver, and pancreas), midgut and hindgut. The foregut (esophagus and stomach) further forms Gastro-Esophageal Junction Neuroendocrine Tumor. To name a few of these companies: ITM Isotopen Technologien München AG, and EpicentRx.

The dynamics of Gastro-Esophageal Junction Neuroendocrine Tumor market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period of 2019-2028. The emerging therapies focused on the treatment of Gastro-Esophageal Junction Neuroendocrine Tumor include 177Lu-edotreotide PRRT (ITM Isotopen Technologien Muenchen), RRx-001 (EpicentRx).

Gastro-Esophageal Junction Neuroendocrine Tumor Report Insights

  • Gastro-Esophageal Junction Neuroendocrine Tumor Patient Population
  • Gastro-Esophageal Junction Neuroendocrine Tumor Therapeutic Approaches
  • Gastro-Esophageal Junction Neuroendocrine Tumor Pipeline Analysis
  • Gastro-Esophageal Junction Neuroendocrine Tumor Market Size and Trends
  • Gastro-Esophageal Junction Neuroendocrine Tumor Market Opportunities
  • Impact of upcoming Gastro-Esophageal Junction Neuroendocrine Tumor Therapies

Gastro-Esophageal Junction Neuroendocrine Tumor (NET) Report Key Strengths

  • 10 Years Forecast
  • Gastro-Esophageal Junction Neuroendocrine Tumor Epidemiology Segmentation
  • Key Cross Competition
  • Gastro-Esophageal Junction Neuroendocrine Tumor Market Size by Therapies
  • Gastro-Esophageal Junction Neuroendocrine Tumor Drugs Uptake

Gastro-Esophageal Junction Neuroendocrine Tumor Report Assessment

  • Gastro-Esophageal Junction Neuroendocrine Tumor Pipeline Product Profiles
  • Key Products and Key Players
  • Gastro-Esophageal Junction Neuroendocrine Tumor Market Drivers and Barriers

Key Benefits

  • The report will help in creating business systems by understanding patterns forming and driving the Gastro-Esophageal Junction Neuroendocrine Tumor market
  • Conduct sales and marketing efforts by identifying the best opportunities for Gastro-Esophageal Junction Neuroendocrine Tumor market
  • To know the future market competition in the Gastro-Esophageal Junction Neuroendocrine Tumor market.

Table of content

  1. Key Insights
  2. Gastro-Esophageal Junction Neuroendocrine Tumor Market Overview at a Glance

2.1. Gastro-Esophageal Junction Neuroendocrine Tumor Market percentage distribution in 2017

2.2. Gastro-Esophageal Junction Neuroendocrine Tumor Market percentage distribution in 2028

  1. Gastro-Esophageal Junction Neuroendocrine Tumor: Disease Overview

3.1. Introduction

3.2. Causes

3.3. Signs and Symptoms

3.4. Risk Factors

3.5. Genetics: Role of P53 Gene

3.6. Gastro-Esophageal Junction Neuroendocrine Tumor Pathology

3.7. Diagnosis

3.7.1.  Gastro-Esophageal Junction Neuroendocrine Tumor Diagnosis

  1. Gastro-Esophageal Junction Neuroendocrine Tumor Epidemiology and Patient Population

4.1. Gastro-Esophageal Junction Neuroendocrine Tumor Key Findings

4.2. United States Gastro-Esophageal Junction Neuroendocrine Tumor Epidemiology

4.2.1. Assumptions and Rationale

4.2.2. Total Gastro-Esophageal Junction Neuroendocrine Tumor Diagnosed Prevalent Cases in the United States

4.2.3. Grade Specific Gastro-Esophageal Junction Neuroendocrine Tumor Diagnosed Prevalent Cases in the United States

  1. Gastro-Esophageal Junction Neuroendocrine Tumor Treatment

5.1. Gastro-Esophageal Junction Neuroendocrine Tumor Treatment Algorithm

  1. Marketed drugs

6.1. Lutathera (lutetium Lu 177 dotatate): Advanced Accelerator Applications S.A. (Novartis)

6.1.1. Product Description

6.1.2. Mechanism of Action

6.1.3. Regulatory Milestones

6.1.4. Other development activities

6.1.5. Safety and Efficacy

6.1.6. Advantages and Disadvantages

6.1.7. Product Profile

  1. Emerging drugs

7.1. Key Cross Competition

7.2. 177Lu-edotreotide PRRT: ITM Isotopen Technologien Muenchen

7.2.1. Product Description

7.2.2. Product Profile

7.2.3. Product Development Activities

7.2.4. Gastro-Esophageal Junction Neuroendocrine Tumor Clinical development

7.2.5. Gastro-Esophageal Junction Neuroendocrine Tumor Clinical Trials Information

7.2.6. Safety and Efficacy

7.3. Anlotinib: Advenchen Laboratories

7.3.1. Product Description

7.3.2. Product Profile

7.3.3. Product Development Activities

7.3.4. Clinical Development

7.3.5. Gastro-Esophageal Junction Neuroendocrine Tumor Clinical Trials Information

7.4. ATG-008: Antengene

7.4.1. Product Description

7.4.2. Product Profile

7.4.3. Product Development Activities

7.4.4. Gastro-Esophageal Junction Neuroendocrine Tumor Clinical development

7.4.5. Gastro-Esophageal Junction Neuroendocrine Tumor Clinical Trials Information

7.4.6. Safety and Efficacy

7.5. Fosbretabulin: Mateon Therapeutics

7.5.1. Product Description

7.5.2. Product Profile

7.5.3. Product Development Activities

7.5.4. Clinical development

7.5.5. Clinical Trials Information

7.5.6. Safety and Efficacy

7.6. RRx-001: EpicentRx

7.6.1. Product Description

7.6.2. Product Profile

7.6.3. Product Development Activities

7.6.4. Clinical development

7.6.5. Gastro-Esophageal Junction Neuroendocrine Tumor Clinical Trials Information

7.6.6. Safety and Efficacy

7.7. Satoreotide tetraxetan: Ipsen

7.7.1. Product Description

7.7.2. Product Profile

7.7.3. Product Development Activities

7.7.4. Clinical development

7.7.5. Gastro-Esophageal Junction Neuroendocrine Tumor Clinical Trials Information

7.8. CVM-1118 (TRX-818): TaiRx

7.8.1. Product Description

7.8.2. Product Profile

7.8.3. Product Development Activities

7.8.4. Clinical development

7.8.5. Clinical Trials Information

7.9. ABI-009: Aadi Bioscience

7.9.1. Product Description

7.9.2. Product Profile

7.9.3. Product Development Activities

7.9.4. Clinical development

7.9.5. Clinical Trials Information

  1. Gastro-Esophageal Junction Neuroendocrine Tumor Unmet Needs
  2. Gastro-Esophageal Junction Neuroendocrine Tumor Market Analysis: United States

9.1. Key Findings

  1. Gastro-Esophageal Junction Neuroendocrine Tumor Market Outlook: The United States

10.1. The United States Market Size

10.1.1. Total Gastro-Esophageal Junction Neuroendocrine Tumor Market size

10.1.2. Total Gastro-Esophageal Junction Neuroendocrine Tumor Market size  by First-line of Therapies

10.1.3. Total Gastro-Esophageal Junction Neuroendocrine Tumor Market size by Second-line of Therapies

10.1.4. Total Gastro-Esophageal Junction Neuroendocrine Tumor Market Size by Therapies

  1. Gastro-Esophageal Junction Neuroendocrine Tumor Market Drivers
  2. Gastro-Esophageal Junction Neuroendocrine Tumor Market Barriers
  3. Appendix

13.1. Gastro-Esophageal Junction Neuroendocrine Tumor Report Methodology

  1. DelveInsight Capabilities
  2. Disclaimer
  3. About DelveInsight

DelveInsight is a premier Business Consulting & Market Research organization, focused exclusively on the life science section. Along with a wide array of advanced end-to-end resolutions, the company assist the universal Pharmaceutical & Bio-Tech firms in formulating prudent commerce assessments for improving their performances to stay afore of the competitors. The organizations prescribe the primary decision-makers in the industry on critical problems and also furthermore informs them of the several opportunities prevailing in the market.

For more information or any query which is related to Gastro-Esophageal Junction NET Market Insight then visit here- Gastro-Esophageal Junction NET Market Insight, Epidemiology and Market Forecast 2028

Contact Us:-

Shruti Thakur

[email protected] | www.delveinsight.com

+91-9650213330

This post was originally published on The Market Plan